Theratechnologies Inc. (NASDAQ:THTX – Get Free Report) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 38,400 shares, a decline of 53.5% from the December 31st total of 82,500 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 93,600 shares, the short-interest ratio is currently 0.4 days.
Theratechnologies Price Performance
Shares of NASDAQ THTX traded down $0.09 during midday trading on Thursday, hitting $1.50. 26,450 shares of the company’s stock were exchanged, compared to its average volume of 105,180. Theratechnologies has a twelve month low of $1.08 and a twelve month high of $2.18. The firm has a market cap of $68.97 million, a P/E ratio of -15.00 and a beta of 1.30. The stock’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.42.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Theratechnologies stock. Cyndeo Wealth Partners LLC grew its position in shares of Theratechnologies Inc. (NASDAQ:THTX – Free Report) by 26.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 131,311 shares of the company’s stock after purchasing an additional 27,191 shares during the quarter. Cyndeo Wealth Partners LLC owned 0.29% of Theratechnologies worth $163,000 as of its most recent filing with the SEC.
About Theratechnologies
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
See Also
- Five stocks we like better than Theratechnologies
- The Most Important Warren Buffett Stock for Investors: His Own
- How Value Investors Find Undervalued Stocks and Build Wealth
- Stock Average Calculator
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
- Learn Technical Analysis Skills to Master the Stock Market
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
